Dysuria caused by pelvic metastasis from breast carcinoma was alleviated by multi-modality therapy with zoledronic acid.
Tanaka
Yuko
Y
Morimoto
Shinji
S
Maeda
Manabu
M
Naganuma
Toshihiro
T
D000230:Adenocarcinoma / Q000556:secondary*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001707:Biopsy, Needle; D001943:Breast Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000627:therapeutic use*; D053159:Dysuria / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007150:Immunohistochemistry; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D000077268:Pamidronate; D010386:Pelvic Neoplasms / Q000556:secondary* / Q000628:therapy*; D018714:Radiotherapy, Adjuvant; D020127:Recovery of Function; D013997:Time Factors; D016896:Treatment Outcome; D018608:Ultrasonography, Doppler; D014546:Urinary Catheterization / Q000379:methods; D016055:Urinary Retention / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D000077211:Zoledronic Acid
D018931:Antineoplastic Agents, Hormonal; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D000077268:Pamidronate